Skip to main content
. 2016 Jun 14;7:11856. doi: 10.1038/ncomms11856

Figure 4. In vivo BLI of cancer cells using AkaLumine-HCl.

Figure 4

(a) Bioluminescence spectrum from subcutaneous tumours. Bioluminescence (BL) intensity was measured with 18 filters (500–840 nm) in IVIS Spectrum after injection of D-luciferin (D-luci), CycLuc1 and AkaLumine-HCl (Aka-HCl) into mice bearing subcutaneous LLC/luc tumours. Date are representative of three independent experiments. (b) Half-life of AkaLumine-HCl in serum. Recombinant Fluc proteins were reacted with blood sampled at indicated time after intraperitoneal injection of 5 mM AkaLumine-HCl. Representative BL images (upper) and quantitative analysis (bottom) of BL intensity generated by reaction with recombinant Fluc proteins and AkaLumine-HCl in sampled blood are shown. n=3. (c) Representative BL images of LLC/luc subcutaneous tumours and (d) quantitative analysis of BL production 15 min after intraperitoneal injection of 100 μl of D-luciferin (D-luci) or AkaLumine-HCl (Aka-HCl) with indicated concentration. n=6, *P<0.05 (t-test). The substrates were injected to the same mouse in the order of D-luci and Aka-HCl at a 4-h interval. Error bars indicate s.e.m.